Tebentafusp

Summary

Tebentafusp (CHEMBL4297990) is an approved protein (ATC L01XX75); indicated across 4 conditions including melanoma and uveal cancer.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: L01XX75
• Indications: 4 conditions
• Clinical trials: 19

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297990
Name	Tebentafusp
Type	Protein
Max phase	4
ATC	L01XX75

Also known as: IMCGP-100, Imcgp100, IMCGP100, IMCgp 100, IMMTAC IMCGP100, ImmTAC IMCgpgp 100, Kimmtrak, Tebentafusp, Tebentafusp tebn, Tebentafusp-tebn, TEBENTAFUSP

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
melanoma	4	MONDO:0005105	EFO:0000756
uveal cancer	4	MONDO:0002659	EFO:1001230
neoplasm	4	MONDO:0005070	EFO:0000616
uveal melanoma	3	MONDO:0006486	EFO:1000616

Clinical trials

Total trials: 19.

Phase distribution

Phase	Trials
PHASE2	9
PHASE1/PHASE2	4
PHASE3	2
PHASE1	2
EARLY_PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05549297	PHASE3	RECRUITING	Tebentafusp Regimen Versus Investigator’s Choice in Previously Treated Advanced Melanoma (TEBE-AM)
NCT06246149	PHASE3	RECRUITING	Adjuvant Tebentafusp in High Risk Ocular Melanoma
NCT04262466	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
NCT05315258	PHASE2	ACTIVE_NOT_RECRUITING	Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma
NCT06070012	PHASE2	RECRUITING	Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
NCT06414590	PHASE2	RECRUITING	Neoadjuvant Tebentafusp for Uveal Melanoma
NCT06626516	PHASE1/PHASE2	RECRUITING	Tebentafusp-tebn With LDT in Metastatic UM
NCT06627244	PHASE2	RECRUITING	Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
NCT06942442	PHASE2	RECRUITING	A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
NCT07057596	PHASE2	RECRUITING	Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma
NCT07276386	PHASE2	RECRUITING	Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
NCT02535078	PHASE1/PHASE2	WITHDRAWN	Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma
NCT02570308	PHASE1/PHASE2	COMPLETED	A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
NCT02889861	PHASE2	TERMINATED	IMCgp100-401 Rollover Study
NCT03070392	PHASE2	COMPLETED	Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
NCT05785754	PHASE1	RECRUITING	DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
NCT01211262	PHASE1	COMPLETED	Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
NCT01209676	EARLY_PHASE1	COMPLETED	IMCgp100 in Advanced Unresectable Melanoma
NCT04960891	Not specified	AVAILABLE	A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).